🔴 Corcept Therapeutics is trading 4.12% down in pre-market; immediate catalyst remains unclear

Corcept Therapeutics is trading 4.12% down in pre-market at $106.25, with the immediate catalyst unclear.

• It fell from the September 15 close of $110.82; no clear company-specific announcement, earnings release, regulatory action, or analyst change explains the September 16 pre-market decline.
• Recent coverage highlights strong second-quarter results and raised guidance, while broader markets are modestly higher.
• The move may reflect stock-specific selling or delayed valuation and insider-sale concerns, but causation is unestablished; confidence is low.